Asymptomatic presentation of silent uterine perforation by Cu-T 380A: a case report with review of literature
Keywords:
Cu-T 380A, Silent uterine perforation, Asymptomatic, IUCDAbstract
Copper containing intrauterine contraceptive device are used worldwide and considered to be safe, effective, reversible and long term method of birth control. While IUCDs are tolerated well by most of the women, they are also associated with adverse effects like bleeding and dysmenorrhea. Uterine perforation during Cu-T insertion is one of the rarest complications and 30% of which are asymptomatic and can be presented with serious complications if not diagnosed early. This complication can be avoided if proper techniques are used by gynaecologists and health professionals. Education and counseling of the women about feeling the IUCD string after every menstrual cycle and post insertion of IUCD is equally important to facilitate the early detection of misplaced IUCD to prevent serious complications like uterine perforation.
Metrics
References
Brigid Fitzgerald Reading. Growth in world contraceptive use stalling; 215 million women’s needs still unmet. Earth Policy Institute, 2012. Available at: http://www.earth-policy.org/data_highlights/2012/highlights26. Accessed 4 October 2013.
United Nations. Department of Economic and Social Affairs. Population Division. World contraceptive use 2005, 2006. Available at: http://www.un.org/esa/population/publications/contraceptive2005/WCU2005.htm.
Sonfield Adam. Popularity disparity: attitudes about the IUD in Europe and the United States. Guttmacher Policy Rev. 2007;10(4):19-24.
Heartwell SF, Schlesselman S. Risk of Uterine perforation among users of intra uterine device. Obstet Gynaecol. 1983;61:31-6.
Chi IC, Kelly E. Is lactation a risk factor of IUD- and sterilization-related uterine perforation? A hypothesis. Int J Gynaecol Obstet. 1984 Aug;22(4):315-7.
World Health Organization (WHO). Mechanism of action, safety and efficacy of intrauterine devices. In: WHO, eds. Repot of a WHO Scientific Group: Technical report series 753. Geneva: World Health Organization; 1987: 22.
K. Van Houdenhovena T, K. J. A. F. van Kaamb, A. C. van Grootheestc, T. H. B. Salemansd, G. A. J. Dunselmanb. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception. 2006;73:257-60.
Kaislasuo J, Suhonen S, Gissler M, Lähteenmäki P, Heikinheimo O. Uterine perforation caused by intrauterine devices: clinical course and treatment. Hum Reprod. 2013 Jun;28(6):1546-51.
Zakin D, Stern WZ, Rosenblatt R. Complete and partial uterine perforation and embedding following insertion of intrauterine devices: Classification, complications, mechanism, incidence, and missing string. Obstet Gynaecol Surv. 1981;36:335-53.
Chi IC, Potts M, Wilkens L, Champion CB. Performance of the TCu380A device in breastfeeding and non-breastfeeding women. Contraception. 1989;39:603-18.
Buhling KJ, Zite NB, Lotke P, Black K. INTRA Writing Group. Worldwide use of intrauterine contraception: a review. Contraception. 2014 Mar;89(3):162-73.
ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update. 2008 May-Jun;14(3):197-208.
Hubacher D, Reyes V, Lillo S, Pierre-Louis B, Zepeda A, Chen PL, et al. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod. 2006;21:1467-72.
Istanbulluoglu MO, Ozcimen EE, Ozturk B. Bladder perforation related to intrauterine device. J Chin Med Assoc. 2008;71:207-9.
